FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS

The FDA has approved ofatumumab (Kesimpta) as the first self-administered, targeted B-cell therapy for adults with relapsing forms of multiple sclerosis.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news